Sort   by:  
 Page size 
MetabolomicsMetabolomic Responses of Arabidopsis Suspension Cells to Bicarbonate under Light and Dark Conditions
Global CO2 level presently recorded at 400 ppm is expected to reach 550 ppm in 2050, an increment likely to impact plant growth and productivity. Using targeted LC-MS and GC-MS platforms we quantified 229 and 29 metabolites, respectively in a time-course study to reveal short-term responses to diffe...
2017-04-25 | MTBLS311 | MetaboLights
UnknownLongitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies.
Not available
S-EPMC8678205 | biostudies-literature
UnknownExome sequencing in paediatric patients with movement disorders.
Not available
S-EPMC7809769 | biostudies-literature
GenomicsEGAD00000000119
Genotypes from cell lines derived from breast carcinoma tissue
EGAD00000000119 | EGA
GenomicsAssessment of genomic copy number alterations in breast cancer
The aim of this study was to assess genomic copy number alterations in a panel of breast cancer cell lines. These data were used to identify common aberrations associated with breast cancer, and also to identify aberrations associated with response to therapeutic compounds.
EGAS00000000059 | EGA
GenomicsBreast Cancer Cell Line Data Access Committee
Access to data is available by emailing application to the data access committee and will be granted to qualified investigators for appropriate use.
EGAC00000000015 | EGA
ProteomicsWEHI991 drug target identification by DIA Solvent PISA
Here we demonstrate PfSTART1 engagement by WEHI991 in the P. falciparum proteome using organic solvent-based Proteome Integral Solubility Alteration (Solvent PISA) assay coupled with Data Independent Acquisition Mass Spectrometry (DIA-MS).
ORGANISM(S): Plasmodium (plasmodium) 
2024-05-01 | PXD048262 | JPOST Repository
UnknownComparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia.
Not available
S-EPMC10311390 | biostudies-literature
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Not available
S-EPMC9862372 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
Sort   by:  
 Page size